Merck is deploying substantial capital to acquire differentiated clinical-stage assets—an oral CML therapy and a long-acting influenza prophylactic—that address large patient populations with distinct mechanisms, while external funding partnerships defray development risk.
the thesis · admitted · the reason above is the thesis, not printed twice
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedsix sentences · whole, uncut
the claims it rests on · in our words, not the filing’s
In May 2026, Merck acquired Terns Pharmaceuticals for $6.8 billion